We are looking forward to the outcomes of the research eagerly. Results We determined 141 published information, and 4 research (composed of 2202 sufferers) were contained in the evaluation. Immunotherapy (including ipilimumab, atezolizumab, and durvalumab) plus chemotherapy was connected with better Operating-system (hazard proportion (HR) 0.84, 95% self-confidence period (CI) 0.75C0.93; risk proportion (RR) 0.90, […]